Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
IgE and eosinophils as therapeutic targets in asthma
Tanvi R. Patel, Sanjiv Sur
Research output
:
Contribution to journal
›
Review article
›
peer-review
44
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'IgE and eosinophils as therapeutic targets in asthma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Asthma
100%
Eosinophils
100%
Biological Agents
100%
Therapeutic Target
100%
Health Care Costs
75%
Healthcare Utilization
75%
Patient Characteristics
50%
Severe Asthma
50%
Omalizumab
50%
Biologic Therapy
50%
Emergency Admissions
50%
Emergency Visits
50%
Eosinophilic Asthma
50%
United States
25%
Th2 Cytokines
25%
Hospitalization
25%
Chronic Inflammatory Diseases
25%
Asthma Control
25%
Moderate-to-severe Asthma
25%
Quality of Life Assessment
25%
Allergic Asthma
25%
Interleukin-5 (IL-5)
25%
Pathophysiologic Mechanisms
25%
Symptom Score
25%
Biological Therapy
25%
Benralizumab
25%
Asthma Symptoms
25%
Emergency Department Visits
25%
Chronic Airflow Obstruction
25%
Beneficial Role
25%
Anti-IgE Antibody
25%
Atopic Disease
25%
Severe Persistent Asthma
25%
Multiple Patients
25%
Mepolizumab
25%
Productivity Loss
25%
Reslizumab
25%
Urgent Care
25%
Characteristic Mechanisms
25%
Dupilumab
25%
Overall Benefit
25%
Medicine and Dentistry
Immunoglobulin E
100%
Asthma
100%
Eosinophil
100%
Biological Product
66%
Health Care Cost
50%
Severe Asthma
50%
Biological Therapy
50%
Patient Characteristics
33%
Cytokine
33%
Eosinophilic
33%
Omalizumab
33%
Disease
16%
Airway Obstruction
16%
Inflammatory Disorder
16%
Quality of Life
16%
Emergency Department
16%
Patient with Asthma
16%
Urgent Care
16%
Interleukin 5
16%
Immunoglobulin E Antibody
16%
Atopy
16%
Dupilumab
16%
Severe Persistent Asthma
16%
Reslizumab
16%
Eosinophil in Asthma
16%
Mepolizumab
16%
Benralizumab
16%
Immunology and Microbiology
Asthma
100%
Immunoglobulin E
100%
Eosinophil Granulocyte
100%
Biological Product
50%
Severe Asthma
37%
Cytokine
25%
Omalizumab
25%
Immunoglobulin E Antibody
12%
Inflammatory Disorder
12%
Atopy
12%
Interleukin 5
12%
Airflow
12%
Severe Persistent Asthma
12%
Benralizumab
12%
Reslizumab
12%
Dupilumab
12%
Mepolizumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Immunoglobulin E
100%
Asthma
100%
Biological Product
36%
Disease
18%
Cytokine
18%
Omalizumab
18%
Airway Obstruction
9%
Atopy
9%
Immunoglobulin E Antibody
9%
Benralizumab
9%
Interleukin 5
9%
Severe Persistent Asthma
9%
Dupilumab
9%
Mepolizumab
9%
Reslizumab
9%